STA
NBIX icon

Summit Trail Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Summit Trail Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$505K Buy
3,835
+916
+31% +$122K 0.01% 1163
2025
Q4 		$414K Buy
2,919
+172
+6% +$24.9K 0.01% 1132
2025
Q3 		$386K Buy
2,747
+1,028
+60% +$139K 0.01% 1148
2025
Q2 		$216K Buy
+1,719
New +$197K ﹤0.01% 1033
2018
Q1 		– Sell
-155
Closed -$14K – 1226
2017
Q4 		$14K Buy
+155
New +$10.6K ﹤0.01% 1133

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Summit Trail Advisors's NBIX Position: Q1 2026 in Review

Summit Trail Advisors increased its Neurocrine Biosciences (NBIX) stake by 31% in Q1 2026, buying an estimated $122K and bringing the position to 3,835 shares worth $505K. The position accounts for 0.01% of the portfolio, ranked #1163.

Summit Trail Advisors first reported a position in NBIX in Q4 2017 and has held it in 5 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Summit Trail Advisors held 3,835 shares of Neurocrine Biosciences worth $505K as of Q1 2026.
  • Summit Trail Advisors bought 916 Neurocrine Biosciences shares in Q1 2026, an estimated $122K.
  • Neurocrine Biosciences made up 0.01% of Summit Trail Advisors's portfolio in Q1 2026, its #1163 holding.
  • Summit Trail Advisors first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 5 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.